Fig. 2From: Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective dataPFS and OS of RET fusion positive NSCLC patients treated with ICI based therapies. (A) the mPFS of RET fusion positive NSCLC patients treated with ICIs; (B) the mOS of RET fusion positive NSCLC patients treated with ICIsBack to article page